Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dalian Holley Kingkong Pharmaceutical Co., Ltd | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
Patients with advanced primary liver cancer will be enrolled in the trial , then the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .The purpose of the study is to evaluate the effect and safety of the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment in the treatment of advanced primary liver cancer
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Elemene + the best supportive treatment | Experimental | the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment . |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Elemene Injection/Elemene Oral Emulusion | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| DCR and/or 6-months survival rate | Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease/ | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| ORR | Objective response rate.The proportion of patients who had a best response rating of complete response and partial response. | 1year |
| PFS | Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shukui Qin | Contact | 025-80864541 | qinsk@csco.org.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Henan Medical University Cancer Hospital | Recruiting | Zhengzhou | Henan | 450000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment
Not provided
Not provided
Not provided
Not provided
| 1 year |
| OS | Overrall survival.The time of patient from randomization to death caused by any cause | 3 year |
| QLQ | Quality of Life Questionnaire Core 30 | 3 year |
| the rate of incidence of adverse events | NCI CTC AE 4.03 | 3 year |
| ID | Term |
|---|---|
| C038905 | elemene |
Not provided
Not provided
Not provided